Literature DB >> 20499290

Monitoring antiretroviral therapy in resource-limited settings: balancing clinical care, technology, and human resources.

Mina C Hosseinipour1, Mauro Schechter.   

Abstract

Due to the rapid expansion of first-line antiretroviral therapy in resource-limited settings (RLS), increasing numbers of people are living with HIV for prolonged periods of time. Treatment programs must now decide how to balance monitoring costs necessary to maximize health benefits for those already on treatment with the continued demand to initiate more patients on first-line treatment. We review currently available evidence related to monitoring strategies in RLS and discuss their implications on timing of switching to second-line treatment, development of HIV resistance, and clinical outcome.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20499290     DOI： 10.1007/s11904-010-0046-4

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN： 1548-3568            Impact factor:   5.071


  40 in total

1.  Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.

Authors:  Arthi Vijayaraghavan; Molly Bates Efrusy; Peter D Mazonson; Osman Ebrahim; Ian M Sanne; Christopher C Santas
Journal:  J Acquir Immune Defic Syndr       Date:  2007-09-01       Impact factor: 3.731

2.  Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.

Authors:  Eran Bendavid; Sean D Young; David A Katzenstein; Ahmed M Bayoumi; Gillian D Sanders; Douglas K Owens
Journal:  Arch Intern Med       Date:  2008-09-22

3.  Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings.

Authors:  Rami Kantor; Lameck Diero; Allison Delong; Lydia Kamle; Sarah Muyonga; Fidelis Mambo; Eunice Walumbe; Wilfred Emonyi; Philip Chan; E Jane Carter; Joseph Hogan; Nathan Buziba
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

4.  Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

Authors:  José R Arribas; Federico Pulido; Rafael Delgado; Alicia Lorenzo; Pilar Miralles; Alberto Arranz; Juan J González-García; Concepción Cepeda; Rafael Hervás; José R Paño; Francisco Gaya; Antonio Carcas; María L Montes; José R Costa; José M Peña
Journal:  J Acquir Immune Defic Syndr       Date:  2005-11-01       Impact factor: 3.731

5.  Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

Authors:  Federico Pulido; Rafael Delgado; Ignacio Pérez-Valero; Juan González-García; Pilar Miralles; Alberto Arranz; Asunción Hernando; José R Arribas
Journal:  J Antimicrob Chemother       Date:  2008-03-13       Impact factor: 5.790

6.  Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy.

Authors:  Olivia Keiser; Patrick MacPhail; Andrew Boulle; Robin Wood; Mauro Schechter; François Dabis; Eduardo Sprinz; Matthias Egger
Journal:  Trop Med Int Health       Date:  2009-07-14       Impact factor: 2.622

7.  Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.

Authors:  Andrew N Phillips; Deenan Pillay; Alec H Miners; Diane E Bennett; Charles F Gilks; Jens D Lundgren
Journal:  Lancet       Date:  2008-04-26       Impact factor: 79.321

8.  Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.

Authors:  Vincent C Marconi; Henry Sunpath; Zhigang Lu; Michelle Gordon; Kofi Koranteng-Apeagyei; Jane Hampton; Steve Carpenter; Janet Giddy; Douglas Ross; Helga Holst; Elena Losina; Bruce D Walker; Daniel R Kuritzkes
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

9.  Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

Authors:  P Mugyenyi; A S Walker; J Hakim; P Munderi; D M Gibb; C Kityo; A Reid; H Grosskurth; J H Darbyshire; F Ssali; D Bray; E Katabira; A G Babiker; C F Gilks; H Grosskurth; P Munderi; G Kabuye; D Nsibambi; R Kasirye; E Zalwango; M Nakazibwe; B Kikaire; G Nassuna; R Massa; K Fadhiru; M Namyalo; A Zalwango; L Generous; P Khauka; N Rutikarayo; W Nakahima; A Mugisha; J Todd; J Levin; S Muyingo; A Ruberantwari; P Kaleebu; D Yirrell; N Ndembi; F Lyagoba; P Hughes; M Aber; A Medina Lara; S Foster; J Amurwon; B Nyanzi Wakholi; J Whitworth; K Wangati; B Amuron; D Kajungu; J Nakiyingi; W Omony; K Fadhiru; D Nsibambi; P Khauka; P Mugyenyi; C Kityo; F Ssali; D Tumukunde; T Otim; J Kabanda; H Musana; J Akao; H Kyomugisha; A Byamukama; J Sabiiti; J Komugyena; P Wavamunno; S Mukiibi; A Drasiku; R Byaruhanga; O Labeja; P Katundu; S Tugume; P Awio; A Namazzi; G T Bakeinyaga; H Katabira; D Abaine; J Tukamushaba; W Anywar; W Ojiambo; E Angweng; S Murungi; W Haguma; S Atwiine; J Kigozi; L Namale; A Mukose; G Mulindwa; D Atwiine; A Muhwezi; E Nimwesiga; G Barungi; J Takubwa; S Murungi; D Mwebesa; G Kagina; M Mulindwa; F Ahimbisibwe; P Mwesigwa; S Akuma; C Zawedde; D Nyiraguhirwa; C Tumusiime; L Bagaya; W Namara; J Kigozi; J Karungi; R Kankunda; R Enzama; A Latif; J Hakim; V Robertson; A Reid; E Chidziva; R Bulaya-Tembo; G Musoro; F Taziwa; C Chimbetete; L Chakonza; A Mawora; C Muvirimi; G Tinago; P Svovanapasis; M Simango; O Chirema; J Machingura; S Mutsai; M Phiri; T Bafana; M Chirara; L Muchabaiwa; M Muzambi; J Mutowo; T Chivhunga; E Chigwedere; M Pascoe; C Warambwa; E Zengeza; F Mapinge; S Makota; A Jamu; N Ngorima; H Chirairo; S Chitsungo; J Chimanzi; C Maweni; R Warara; M Matongo; S Mudzingwa; M Jangano; K Moyo; L Vere; N Mdege; I Machingura; E Katabira; A Ronald; A Kambungu; F Lutwama; I Mambule; A Nanfuka; J Walusimbi; E Nabankema; R Nalumenya; T Namuli; R Kulume; I Namata; L Nyachwo; A Florence; A Kusiima; E Lubwama; R Nairuba; F Oketta; E Buluma; R Waita; H Ojiambo; F Sadik; J Wanyama; P Nabongo; J Oyugi; F Sematala; A Muganzi; C Twijukye; H Byakwaga; R Ochai; D Muhweezi; A Coutinho; B Etukoit; C Gilks; K Boocock; C Puddephatt; C Grundy; J Bohannon; D Winogron; D M Gibb; A Burke; D Bray; A Babiker; A S Walker; H Wilkes; M Rauchenberger; S Sheehan; C Spencer-Drake; K Taylor; M Spyer; A Ferrier; B Naidoo; D Dunn; R Goodall; J H Darbyshire; L Peto; R Nanfuka; C Mufuka-Kapuya; P Kaleebu; D Pillay; V Robertson; D Yirrell; S Tugume; M Chirara; P Katundu; N Ndembi; F Lyagoba; D Dunn; R Goodall; A McCormick; A Medina Lara; S Foster; J Amurwon; B Nyanzi Wakholi; J Kigozi; L Muchabaiwa; M Muzambi; I Weller; A Babiker; S Bahendeka; M Bassett; A Chogo Wapakhabulo; J H Darbyshire; B Gazzard; C Gilks; H Grosskurth; J Hakim; A Latif; C Mapuchere; O Mugurungi; P Mugyenyi; C Burke; S Jones; C Newland; G Pearce; S Rahim; J Rooney; M Smith; W Snowden; J-M Steens; A Breckenridge; A McLaren; C Hill; J Matenga; A Pozniak; D Serwadda; T Peto; A Palfreeman; M Borok; E Katabira
Journal:  Lancet       Date:  2009-12-08       Impact factor: 79.321

10.  Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda.

Authors:  Steven J Reynolds; Cissy Kityo; Frank Mbamanya; Robin Dewar; Francis Ssali; Thomas C Quinn; Peter Mugyenyi; Mark Dybul
Journal:  Antivir Ther       Date:  2009
View more
  6 in total

1.  Practices to improve identification of adult antiretroviral therapy failure at the Lighthouse Trust clinic in Lilongwe, Malawi.

Authors:  Charles K Vorkas; Hannock Tweya; Dalitso Mzinganjira; George Dickie; Ralf Weigel; Sam Phiri; Mina C Hosseinipour
Journal:  Trop Med Int Health       Date:  2011-11-01       Impact factor: 2.622

2.  Evaluating the utility of provider-recorded clinical status in the medical records of HIV-positive adults in a limited-resource setting.

Authors:  Samantha Stonbraker; Montina Befus; Leonel Lerebours Nadal; Mina Halpern; Elaine Larson
Journal:  Int J STD AIDS       Date:  2016-08-05       Impact factor: 1.359

Review 3.  Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?

Authors:  N Kumarasamy; Atul Patel; Sanjay Pujari
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

4.  HIV Case Management Support Service Is Associated with Improved CD4 Counts of Patients Receiving Care at the Antiretroviral Clinic of Pantang Hospital, Ghana.

Authors:  Bismark Sarfo; Naa Ashiley Vanderpuye; Abigail Addison; Peter Nyasulu
Journal:  AIDS Res Treat       Date:  2017-09-20

5.  A clinical prediction score in addition to WHO criteria for anti-retroviral treatment failure in resource-limited settings--experience from Lesotho.

Authors:  Niklaus Daniel Labhardt; Thabo Lejone; Matse'liso Setoko; Matalenyane Poka; Jochen Ehmer; Karolin Pfeiffer; Patrice Zinga Kiuvu; Lutgarde Lynen
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

6.  High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.

Authors:  Cissy Kityo; Diana M Gibb; Charles F Gilks; Ruth L Goodall; Ivan Mambule; Pontiano Kaleebu; Deenan Pillay; Ronnie Kasirye; Peter Mugyenyi; A Sarah Walker; David T Dunn
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.